Completed PHASE2 INTERVENTIONAL NCT00002535

Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma

TUMOR INFILTRATING LYMPHOCYTE THERAPY FOR ADVANCED MELANOMA USING IMMUNOMODULATION, A PHASE II STUDY

Sponsor: St. Luke's Medical Center

Interventions aldesleukin cyclophosphamide indomethacin lymphokine-activated killer cells therapeutic tumor infiltrating lymphocytes

Updated 5 times since 2017 Last updated: Jun 25, 2013 Started: Jul 31, 1993 Completion: Jul 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Melanoma (Skin) and is currently completed. St. Luke's Medical Center leads this study, which shows 5 recorded versions since 1993 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jul 1993

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

St. Luke's Medical Center

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Milwaukee, United States